158 related articles for article (PubMed ID: 34864488)
1. A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination.
Hu Z; Chen JP; Xu JC; Chen ZY; Qu R; Zhang L; Yao W; Wu J; Yang H; Lowrie DB; Liu Y; Fan XY
Virology; 2022 Jan; 566():56-59. PubMed ID: 34864488
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
Wang Y; Wang L; Cao H; Liu C
J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.
Ober Shepherd BL; Scott PT; Hutter JN; Lee C; McCauley MD; Guzman I; Bryant C; McGuire S; Kennedy J; Chen WH; Hajduczki A; Mdluli T; Valencia-Ruiz A; Amare MF; Matyas GR; Rao M; Rolland M; Mascola JR; De Rosa SC; McElrath MJ; Montefiori DC; Serebryannyy L; McDermott AB; Peel SA; Collins ND; Joyce MG; Robb ML; Michael NL; Vasan S; Modjarrad K;
Lancet Microbe; 2024 Jun; 5(6):e581-e593. PubMed ID: 38761816
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
[TBL] [Abstract][Full Text] [Related]
5. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.
Srivastava V; Niu L; Phadke KS; Bellaire BH; Cho MW
Front Immunol; 2021; 12():637982. PubMed ID: 33777030
[TBL] [Abstract][Full Text] [Related]
6. Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen.
Ramos-Duarte VA; Orlowski A; Jaquenod de Giusti C; Corigliano MG; Legarralde A; Mendoza-Morales LF; Atela A; Sánchez MA; Sander VA; Angel SO; Clemente M
Vaccine; 2024 May; 42(14):3355-3364. PubMed ID: 38631949
[TBL] [Abstract][Full Text] [Related]
7. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
9. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.
Wørzner K; Sheward DJ; Schmidt ST; Hanke L; Zimmermann J; McInerney G; Karlsson Hedestam GB; Murrell B; Christensen D; Pedersen GK
EBioMedicine; 2021 Jan; 63():103197. PubMed ID: 33422991
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
11. CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization.
Haun BK; Lai CY; Williams CA; Wong TAS; Lieberman MM; Pessaint L; Andersen H; Lehrer AT
Front Immunol; 2020; 11():599587. PubMed ID: 33193454
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.
Yang H; Xie Y; Li S; Bao C; Wang J; Li C; Nie J; Quan Y
Hum Vaccin Immunother; 2024 Dec; 20(1):2364519. PubMed ID: 38880868
[TBL] [Abstract][Full Text] [Related]
13. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
14. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
15. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
Steinbuck MP; Seenappa LM; Jakubowski A; McNeil LK; Haqq CM; DeMuth PC
Sci Adv; 2021 Feb; 7(6):. PubMed ID: 33547083
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
[TBL] [Abstract][Full Text] [Related]
18. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Keech C; Albert G; Cho I; Robertson A; Reed P; Neal S; Plested JS; Zhu M; Cloney-Clark S; Zhou H; Smith G; Patel N; Frieman MB; Haupt RE; Logue J; McGrath M; Weston S; Piedra PA; Desai C; Callahan K; Lewis M; Price-Abbott P; Formica N; Shinde V; Fries L; Lickliter JD; Griffin P; Wilkinson B; Glenn GM
N Engl J Med; 2020 Dec; 383(24):2320-2332. PubMed ID: 32877576
[TBL] [Abstract][Full Text] [Related]
19. MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern.
Wang J; Yin XG; Wen Y; Lu J; Zhang RY; Zhou SH; Liao CM; Wei HW; Guo J
J Med Chem; 2022 Feb; 65(4):3563-3574. PubMed ID: 35108485
[TBL] [Abstract][Full Text] [Related]
20. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.
Kim E; Weisel FJ; Balmert SC; Khan MS; Huang S; Erdos G; Kenniston TW; Carey CD; Joachim SM; Conter LJ; Weisel NM; Okba NMA; Haagmans BL; Percivalle E; Cassaniti I; Baldanti F; Korkmaz E; Shlomchik MJ; Falo LD; Gambotto A
Eur J Immunol; 2021 Jul; 51(7):1774-1784. PubMed ID: 33772778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
